Spartalizumab

Swiss pharmaceutical company Novartis AG (NYSE: NVS) announced Saturday that the phase three COMBI-i trial for a combination of drugs against a type of advanced skin cancer didn't meet the clinical requirements of the evaluation. What Happened: The study was a randomized, double-blind...